Number of the records: 1  

Genetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumors: adjuvant treatment of minimal residual disease after surgery/chemotherapy

  1. 1.
    SYSNO ASEP0346751
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleGenetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumors: adjuvant treatment of minimal residual disease after surgery/chemotherapy
    Author(s) Bubeník, Jan (UMG-J)
    Šímová, Jana (UMG-J) RID
    Source TitleJournal of Balkan Union of Oncology - ISSN 1107-0625
    Roč. 14, č. 1 (2009), s. 169-173
    Number of pages5 s.
    Languageeng - English
    CountryGR - Greece
    Keywordsresidual tumour disease ; HPV16 ; cellular vaccines
    Subject RIVEB - Genetics ; Molecular Biology
    R&D ProjectsGA301/06/0774 GA ČR - Czech Science Foundation (CSF)
    GA301/07/1410 GA ČR - Czech Science Foundation (CSF)
    CEZAV0Z50520514 - UMG-J (2005-2011)
    UT WOS000270421500021
    AnnotationLocal recurrences at the site of tumour resection or after chemotherapy, as well as distant micrometastases represent major problems in oncology. Genetically modified cellular vaccines were found to be efficient against cancer both in experimental models and in tumour-bearing patients. It was also shown in various systems that the efficacy of conventional therapeutic modalities can be supported by adjuvant administration of genetically modified vaccines, as well as by depletion of immunosuppressive immunocyte subsets. The purpose of this review is to summarize and evaluate the results obtained with administration of genetically modified cellular vaccines as well as with depletion of immunosuppressive immunocytes performed as treatment of the minimal residual tumour disease after surgery / chemotherapy in the experimental model of murine tumours mimicking human HPV 16-associated neoplasms. The prospects and limitations of these adjuvant immunotherapeutic modalities will be discussed.
    WorkplaceInstitute of Molecular Genetics
    ContactNikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217
    Year of Publishing2011
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.